EV/FCF Ratio: 22.39x
Is the EV/FCF ratio high or low?
The EV/FCF ratio of 22.39x is 14% above its 5-year average of 19.68x, around the middle of its 5-year range (9.98x–35.18x).
As of Friday, June 26, 2026. 7.63% above its 12-month average of 20.80x.
DGX EV/FCF Ratio Chart
DGX Average EV/FCF Ratio Chart
DGX Current vs Average EV/FCF Ratio Chart
DGX EV/FCF Ratio Metrics
EV/FCF RATIO
22.39x
EV/FCF RATIO AVG TTM
20.80x
EV/FCF RATIO AVG 3Y
22.68x
EV/FCF RATIO AVG 5Y
19.68x
EV/FCF RATIO AVG 10Y
19.58x
EV/FCF RATIO AVG 15Y
19.89x
EV/FCF RATIO AVG 20Y
18.92x
CURRENT VS TTM AVG
+7.63%
CURRENT VS 3Y AVG
-1.29%
CURRENT VS 5Y AVG
+13.76%
CURRENT VS 10Y AVG
+14.34%
CURRENT VS 15Y AVG
+12.58%
CURRENT VS 20Y AVG
+18.36%
DGX Competitors' EV/FCF Ratio
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Quest Diagnostics Incorporated (DGX) | $23.08B | 22.39x | 20.80x | 22.68x | 19.68x |
| BioNTech SE (BNTX)vs › | $23.07B | 7.98x | 20.00x | 6.34x | 11.23x |
| United Therapeutics Corporation (UTHR)vs › | $23.03B | 24.13x | 19.25x | 17.06x | 17.06x |
| Incyte Corporation (INCY)vs › | $22.73B | 13.85x | 16.39x | 96.57x | 65.84x |
| Labcorp Holdings Inc. (LH)vs › | $22.10B | 20.48x | 22.24x | 25.43x | 20.46x |
| Waters Corporation (WAT)vs › | $24.41B | 135.84x | 47.59x | 44.39x | 42.31x |
| West Pharmaceutical Services, Inc. (WST)vs › | $24.79B | 55.01x | 48.84x | 59.32x | 64.74x |
| STERIS plc (STE)vs › | $21.00B | 23.01x | 27.71x | 37.52x | 45.63x |
| Mettler-Toledo International Inc. (MTD)vs › | $25.44B | 34.51x | 33.85x | 33.43x | 38.26x |
| Moderna, Inc. (MRNA)vs › | $26.35B | N/A | 26.90x | 26.23x | 26.23x |
Cash Flow Valuation Comparison
EV/FCF
22.4x
P/FCF
17.4x
FCF Yield
5.74%
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
- EV/FCF accounts for debt and cash through enterprise value
- P/FCF only considers equity value
- EV/FCF can be compared across companies with different debt levels
- Both measure how the market values cash generation
EV/FCF Ratio Formula & Definition
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
EV/FCF Ratio FAQ
- What is the EV/FCF ratio for Quest Diagnostics Incorporated (DGX)?
- The EV/FCF ratio for DGX stock is 22.39x.
- Is Quest Diagnostics Incorporated's EV/FCF ratio high or low?
- The EV/FCF ratio of 22.39x is 14% above its 5-year average of 19.68x, around the middle of its 5-year range (9.98x–35.18x).
- What is the TTM average EV/FCF ratio for Quest Diagnostics Incorporated (DGX)?
- The TTM average EV/FCF ratio for DGX stock is 20.80x.
- What is the 3Y average EV/FCF ratio for Quest Diagnostics Incorporated (DGX)?
- The 3Y average EV/FCF ratio for DGX stock is 22.68x.
- What is the 5Y average EV/FCF ratio for Quest Diagnostics Incorporated (DGX)?
- The 5Y average EV/FCF ratio for DGX stock is 19.68x.
- What is the 10Y average EV/FCF ratio for Quest Diagnostics Incorporated (DGX)?
- The 10Y average EV/FCF ratio for DGX stock is 19.58x.
- What is the 15Y average EV/FCF ratio for Quest Diagnostics Incorporated (DGX)?
- The 15Y average EV/FCF ratio for DGX stock is 19.89x.
- What is the 20Y average EV/FCF ratio for Quest Diagnostics Incorporated (DGX)?
- The 20Y average EV/FCF ratio for DGX stock is 18.92x.
DGX EV/FCF Ratio History
| DATE | EV/FCF RATIO |
|---|---|
| 2026-06-25 | 22.39x |
| 2026-06-24 | 22.12x |
| 2026-06-23 | 21.62x |
| 2026-06-22 | 21.32x |
| 2026-06-18 | 21.44x |
| 2026-06-17 | 21.67x |
| 2026-06-16 | 21.95x |
| 2026-06-15 | 22.04x |
| 2026-06-12 | 22.12x |
| 2026-06-11 | 22.18x |
| 2026-06-10 | 22.18x |
| 2026-06-09 | 22.24x |
| 2026-06-08 | 21.62x |
| 2026-06-05 | 21.88x |
| 2026-06-04 | 21.53x |
| 2026-06-03 | 21.33x |
| 2026-06-02 | 21.28x |
| 2026-06-01 | 21.20x |
| 2026-05-29 | 21.43x |
| 2026-05-28 | 21.54x |
| 2026-05-27 | 21.35x |
| 2026-05-26 | 21.26x |
| 2026-05-22 | 21.46x |
| 2026-05-21 | 21.34x |
| 2026-05-20 | 21.33x |
| 2026-05-19 | 21.05x |
| 2026-05-18 | 21.00x |
| 2026-05-15 | 20.73x |
| 2026-05-14 | 20.84x |
| 2026-05-13 | 21.09x |
| 2026-05-12 | 21.03x |
| 2026-05-11 | 21.00x |
| 2026-05-08 | 20.80x |
| 2026-05-07 | 21.09x |
| 2026-05-06 | 20.94x |
| 2026-05-05 | 21.09x |
| 2026-05-04 | 21.14x |
| 2026-05-01 | 21.24x |
| 2026-04-30 | 21.37x |
| 2026-04-29 | 20.96x |
| 2026-04-28 | 21.44x |
| 2026-04-27 | 21.58x |
| 2026-04-24 | 21.55x |
| 2026-04-23 | 21.82x |
| 2026-04-22 | 22.20x |
| 2026-04-21 | 21.68x |
| 2026-04-20 | 20.96x |
| 2026-04-17 | 20.85x |
| 2026-04-16 | 20.56x |
| 2026-04-15 | 20.56x |
| 2026-04-14 | 20.78x |
| 2026-04-13 | 20.68x |
| 2026-04-10 | 20.57x |
| 2026-04-09 | 21.09x |
| 2026-04-08 | 21.17x |
| 2026-04-07 | 21.00x |
| 2026-04-06 | 21.18x |
| 2026-04-02 | 21.10x |
| 2026-04-01 | 21.07x |
| 2026-03-31 | 20.93x |
| 2026-03-30 | 21.03x |
| 2026-03-27 | 20.89x |
| 2026-03-26 | 21.11x |
| 2026-03-25 | 20.97x |
| 2026-03-24 | 20.94x |
| 2026-03-23 | 20.90x |
| 2026-03-20 | 20.87x |
| 2026-03-19 | 20.78x |
| 2026-03-18 | 20.87x |
| 2026-03-17 | 21.15x |
| 2026-03-16 | 21.18x |
| 2026-03-13 | 21.24x |
| 2026-03-12 | 21.34x |
| 2026-03-11 | 21.31x |
| 2026-03-10 | 21.34x |
| 2026-03-09 | 21.40x |
| 2026-03-06 | 21.20x |
| 2026-03-05 | 21.59x |
| 2026-03-04 | 21.96x |
| 2026-03-03 | 21.95x |
| 2026-03-02 | 22.11x |
| 2026-02-27 | 22.25x |
| 2026-02-26 | 22.18x |
| 2026-02-25 | 21.13x |
| 2026-02-24 | 21.27x |
| 2026-02-23 | 21.10x |
| 2026-02-20 | 20.69x |
| 2026-02-19 | 20.69x |
| 2026-02-18 | 20.85x |
| 2026-02-17 | 20.94x |
| 2026-02-13 | 21.05x |
| 2026-02-12 | 21.05x |
| 2026-02-11 | 21.25x |
| 2026-02-10 | 20.93x |
| 2026-02-09 | 19.79x |
| 2026-02-06 | 19.74x |
| 2026-02-05 | 19.87x |
| 2026-02-04 | 19.62x |
| 2026-02-03 | 19.29x |
| 2026-02-02 | 19.28x |
| 2026-01-30 | 19.44x |
| 2026-01-29 | 19.06x |
| 2026-01-28 | 19.10x |
| 2026-01-27 | 19.22x |
| 2026-01-26 | 19.08x |
| 2026-01-23 | 18.96x |
| 2026-01-22 | 19.05x |
| 2026-01-21 | 19.25x |
| 2026-01-20 | 19.60x |
| 2026-01-16 | 19.64x |
| 2026-01-15 | 19.71x |
| 2026-01-14 | 19.42x |
| 2026-01-13 | 18.87x |
| 2026-01-12 | 18.54x |
| 2026-01-09 | 18.42x |
| 2026-01-08 | 18.69x |
| 2026-01-07 | 18.72x |
| 2026-01-06 | 18.91x |
| 2026-01-05 | 18.34x |
| 2026-01-02 | 18.37x |
| 2025-12-31 | 18.35x |
| 2025-12-30 | 18.51x |
| 2025-12-29 | 18.51x |
| 2025-12-26 | 18.54x |
| 2025-12-24 | 18.54x |
| 2025-12-23 | 18.47x |
| 2025-12-22 | 18.58x |
| 2025-12-19 | 18.55x |
| 2025-12-18 | 18.56x |
| 2025-12-17 | 18.80x |
| 2025-12-16 | 18.76x |
| 2025-12-15 | 19.21x |
| 2025-12-12 | 19.08x |
| 2025-12-11 | 19.00x |
| 2025-12-10 | 18.83x |
| 2025-12-09 | 18.84x |
| 2025-12-08 | 19.02x |
| 2025-12-05 | 19.08x |
| 2025-12-04 | 19.21x |
| 2025-12-03 | 19.08x |
| 2025-12-02 | 19.08x |
| 2025-12-01 | 19.18x |
| 2025-11-28 | 19.62x |
| 2025-11-26 | 19.66x |
| 2025-11-25 | 19.87x |
| 2025-11-24 | 19.73x |
| 2025-11-21 | 19.79x |
| 2025-11-20 | 19.49x |
| 2025-11-19 | 19.36x |
| 2025-11-18 | 19.30x |
| 2025-11-17 | 19.38x |
| 2025-11-14 | 19.44x |
| 2025-11-13 | 19.49x |
| 2025-11-12 | 19.43x |
| 2025-11-11 | 19.59x |
| 2025-11-10 | 19.22x |
| 2025-11-07 | 18.83x |
| 2025-11-06 | 18.59x |
| 2025-11-05 | 18.73x |
| 2025-11-04 | 18.71x |
| 2025-11-03 | 18.78x |
| 2025-10-31 | 18.54x |
| 2025-10-30 | 18.53x |
| 2025-10-29 | 18.45x |
| 2025-10-28 | 18.73x |
| 2025-10-27 | 18.89x |
| 2025-10-24 | 19.05x |
| 2025-10-23 | 19.13x |
| 2025-10-22 | 18.97x |
| 2025-10-21 | 19.25x |
| 2025-10-20 | 22.53x |
| 2025-10-17 | 22.45x |
| 2025-10-16 | 22.20x |
| 2025-10-15 | 22.25x |
| 2025-10-14 | 22.07x |
| 2025-10-13 | 21.83x |
| 2025-10-10 | 21.95x |
| 2025-10-09 | 21.71x |
| 2025-10-08 | 21.65x |
| 2025-10-07 | 21.75x |
| 2025-10-06 | 21.43x |
| 2025-10-03 | 21.51x |
| 2025-10-02 | 21.66x |
| 2025-10-01 | 21.76x |
| 2025-09-30 | 22.55x |
| 2025-09-29 | 22.39x |
| 2025-09-26 | 22.40x |
| 2025-09-25 | 22.07x |
| 2025-09-24 | 22.20x |
| 2025-09-23 | 22.22x |
| 2025-09-22 | 22.01x |
| 2025-09-19 | 21.91x |
| 2025-09-18 | 21.88x |
| 2025-09-17 | 21.78x |
| 2025-09-16 | 21.59x |
| 2025-09-15 | 21.63x |
| 2025-09-12 | 21.84x |
| 2025-09-11 | 21.89x |
| 2025-09-10 | 21.59x |
| 2025-09-09 | 21.82x |
| 2025-09-08 | 21.81x |
| 2025-09-05 | 21.89x |
| 2025-09-04 | 21.58x |
| 2025-09-03 | 21.53x |
| 2025-09-02 | 21.45x |
| 2025-08-29 | 21.72x |
| 2025-08-28 | 21.50x |
| 2025-08-27 | 21.55x |
| 2025-08-26 | 21.61x |
| 2025-08-25 | 21.45x |
| 2025-08-22 | 21.59x |
| 2025-08-21 | 21.92x |
| 2025-08-20 | 21.98x |
| 2025-08-19 | 21.83x |
| 2025-08-18 | 21.48x |
| 2025-08-15 | 21.55x |
| 2025-08-14 | 21.43x |
| 2025-08-13 | 21.48x |
| 2025-08-12 | 21.45x |
| 2025-08-11 | 21.42x |
| 2025-08-08 | 21.29x |
| 2025-08-07 | 21.04x |
| 2025-08-06 | 20.93x |
| 2025-08-05 | 20.95x |
| 2025-08-04 | 20.87x |
| 2025-08-01 | 20.73x |
| 2025-07-31 | 20.41x |
| 2025-07-30 | 20.53x |
| 2025-07-29 | 20.46x |
| 2025-07-28 | 20.45x |
| 2025-07-25 | 20.52x |
| 2025-07-24 | 20.82x |
| 2025-07-23 | 20.69x |
| 2025-07-22 | 25.12x |
| 2025-07-21 | 23.85x |
| 2025-07-18 | 23.90x |
| 2025-07-17 | 24.04x |
| 2025-07-16 | 23.92x |
| 2025-07-15 | 23.85x |
| 2025-07-14 | 24.06x |
| 2025-07-11 | 24.03x |
| 2025-07-10 | 24.39x |
| 2025-07-09 | 24.62x |
| 2025-07-08 | 24.50x |
| 2025-07-07 | 24.66x |
| 2025-07-03 | 24.98x |
| 2025-07-02 | 24.94x |
| 2025-07-01 | 25.23x |
| 2025-06-30 | 25.27x |
| 2025-06-27 | 25.07x |
| 2025-06-26 | 24.99x |
| 2025-06-25 | 25.16x |
| 2025-06-24 | 25.29x |
| 2025-06-23 | 25.27x |
| 2025-06-20 | 25.24x |
| 2025-06-18 | 25.28x |
| 2025-06-17 | 25.19x |
| 2025-06-16 | 25.53x |
| 2025-06-13 | 25.33x |
| 2025-06-12 | 25.20x |
Showing the most recent 260 of 5,031 data points. The chart above shows the full history.
Related Metrics
About Quest Diagnostics Incorporated
Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus, New Jersey, is a premier provider of diagnostic testing, information, and related services, serving clients both domestically and internationally. Its core business involves the development and provision of diverse diagnostic information services, such as routine, advanced clinical, and anatomic pathology testing. While primarily operating under the Quest Diagnostics brand, it also leverages specialized identities like AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum to reach a broad spectrum of clients. Its extensive client base includes patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and other direct healthcare entities. Delivery of these services is facilitated through a robust network comprising laboratories, patient service centers, in-office phlebotomists, call centers, and mobile health professionals including paramedics and nurses. Additionally, the company provides risk assessment services for the life insurance industry and offers comprehensive information technology solutions to healthcare organizations and clinicians.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- James E. Davis